UVA Pharmacology Emeriti Professors John Lazo and Elizabeth Sharlow, who are co-founders of the pharmaceutical company KeViRx, Inc. have been granted $1.99 million to advance their first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury (ALI).
Read the details about their research and the award in this Newswire article.
View more details about their company, KeViRx, here.
Comments